Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis

• Published in: World journal of gastroenterology : WJG 2017-06, Vol.23 (22), p.4039-4046
• Main Authors: Matusiewicz, Malgorzata, Neubauer, Katarzyna, Bednarz-Misa, Iwona, Gorska, Sabina, Krzystek-Korpacka, Malgorzata
• Format: Article
• Language: English
• Subjects: Adult; Anemia - blood; Anemia - etiology; Anemia - pathology; Biomarkers - blood; Cachexia - blood; Cachexia - etiology; Cachexia - pathology; Case Control Study; Case-Control Studies; Colitis, Ulcerative - blood; Colitis, Ulcerative - complications; Colitis, Ulcerative - pathology; Colon - pathology; Colonoscopy; Female; Flow Cytometry; Humans; Interleukin-9 - blood; Intestinal Mucosa - pathology; Male; Middle Aged; Wound Healing; Young Adult
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v23.i22.4039

AIM To evaluate circulating IL9 in inflammatory bowel disease and disease-associated anemia/cachexia and assess its potential as a mucosal healing marker.METHODS Serum IL9 as well as other cytokines(IL1β, IL6, IL13, IFNγ, TNFα, and VEGF-A) were determined in 293 individuals: 97 patients with Crohn’s disease(CD) and 74 with ulcerative colitis(UC) and in 122 apparently healthy controls. The clinical activity of CD and UC was expressed in terms of the Crohn’s Disease Activity Index(CDAI) and the Mayo Scoring System(MDAI), respectively, and the severity of bowel inflammation in UC patients was assessed using Mayo endoscopic score. Cytokine concentrations were measured by a flow cytometry-based method using Luminex x MAP? technology. Highsensitive C-reactive protein concentrations(hs CRP) were determined in CD and UC patients using the enhanced immunoturbidimetric method.RESULTS Systemic IL9 was significantly lower in healthy individuals [9 pg/m L(95%CI: 8.2-10)] than in patients with inflammatory bowel disease(IBD): both inactive [14.3 pg/m L(11.9-19.9)] and active (27.6 pg/m L(24.5-32), P < 0.0001)Cytokine concentrations were significantly higher in active CD [27.4 pg/m L(23.4-32.2)] and in active UC [32.7 pg/m L(27-38.9)] compared to inactive diseases (15.9 pg/m L(10.8-23.4) in CD and 19.4 pg/m L(13.9-27.1) in UC, P = 0.001)IL9 correlated weakly with CDAI(ρ = 0.32, P = 0.003) and MDAI(ρ = 0.35, P = 0.002) and strongly with endoscopic inflammation in UC(ρ = 0.74, P < 0.0001). As a negative marker of mucosal healing(MH), IL9 had an accuracy superior to hs CRP and IL6 (97%(P < 0.0001), 67%(P = 0.071), and 55%(P = 0.525), respectively)IL9 was significantly higher in cachectic IBD patients [30.25 pg/m L(24.4-37.5) vs 21.88 pg/m L(18-26.5), P = 0.026] and negatively correlated with hemoglobin concentrations(ρ =-0.27, P < 0.001). Multiple regression showed IL1β and IL13 to be the independent predictors of circulating IL9 in healthy individuals, IFNγ or IL6 in active and inactive UC, respectively, and IL13 and VEGF-A in both active and inactive CD.CONCLUSION The systemic IL9 level is higher in IBD and corresponds with endoscopic inflammation, suggesting its possible application as a negative marker of mucosal healing in UC.